ClinicalTrials.gg
RecruitingNCT07065721CAPAZ-2DUpdated Nov 9, 2026

Continuous Glucose Monitoring for Self-Management of Type 2 Diabetes in Young Adults

An interventional study of Continuous glucose monitor in Type 2 Diabetes Mellitus (T2DM), sponsored by San Diego State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by San Diego State University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 9, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
1,966th of 2,961
45 · median 90
Started
2025
with 138 others
No phase
1,242 of 3,308
200 open now
Primary completion
2026-12
later than 144 of 477 live
Registered
3,096th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,966th largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 139 that started in 2025, is one of 1,242 with no phase, reaches primary completion later than 144 of the 477 other live ones, and was the 3,096th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

Type 2 diabetes in increasing common in young adults. Utilizing a mixed-methods, community-based approach, this study offers continuous glucose monitors (CGMs) to young adults with type 2 diabetes for 30 days, and collects both quantitative and qualitative data to understand barriers and facilitators of CGM use, participants' changes in awareness of glucose patterns while using the CGM, and preferences for a CGM-based self-management intervention.

Read the detailed description

The prevalence of type 2 diabetes (T2D) is rising in young adults and is associated with increased complications and reduced life expectancy. Poor adherence to diabetes self-management behaviors is common in young adulthood, often leading to poor glycemic control, and existing self-management interventions have had limited effectiveness in this age group. Continuous glucose monitors (CGMs) provide real-time glucose data that can support behavior change and reduce common self-management barriers such as glycemic unawareness, but their use in younger adults is limited. As "digital natives," young adults are well-poised to benefit from CGM interventions, particularly if they reduce barriers of standard self-management education (e.g., time burden). Qualitative data has shown that young adults are interested in CGM use but lack both access to CGMs and understanding of how to best utilize CGM data. The purpose of this proposal is to utilize a mixed-methods, community-engaged approach to generate pilot data for the development of a self-management intervention that pairs CGM glucose data with behavioral data (e.g., FitBit step count, dietary intake) to improve self-management and glycemic awareness and control. Young adults with T2D will be recruited to participate in a 30-day trial wear of CGMs, during which self-management behaviors will also be assessed. Afterward, qualitative interviews with participants will be conducted to understand barriers and facilitators of CGM use, changes in awareness of glucose patterns, and preferences for a CGM-based intervention.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • continuous glucose monitor
  • type 2 diabetes
  • young adult
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult 18-45 years of age
  • diagnosis of type 2 diabetes in the last 5 years, as evidenced in the electronic medical record
  • no prior use or experience with wearable CGMs
  • possession of a smart phone that is compatible with Dexcom CGM sensors (nearly all smartphones are compatible) and willing to download and utilize the Dexcom CGM app
  • fluency in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • severe mental illness (e.g., psychosis, suicidal ideation);
  • pregnancy or \<6 months postpartum
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    CGM Wear

    Participants will wear a continuous glucose monitor for 30 days. They will also wear a FitBit activity tracker watch and complete weekly surveys to report diabetes self-management behaviors.

    Device: Continuous glucose monitor

Interventions

  • DeviceContinuous glucose monitor

    Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.

06

What researchers measure

Primary outcomes

  1. Qualitative data regarding CGM use

    Semi-structured qualitative interviews will be conducted to understand barriers and facilitators of CGM use, changes in awareness of glucose patterns or relationships between glucose and health behaviors, and preferences for a future CGM-based intervention.

    Time frame: Immediately after the intervention

Secondary outcomes

  1. Acceptability and feasibility of CGM wear

    Mean rating of CGM feasibility, acceptability, utility, satisfaction ≥ 3/5 on a 0-5 scale

    Time frame: Immediately after the intervention

Other outcomes

  1. Glucose time-in-range

    Percent of time that glucose readings are in target range (70-180 mg/dL)

    Time frame: 30 days (during the intervention period)

  2. Diabetes self-care behaviors

    Self-report of diabetes self-management behaviors (e.g., healthy eating, physical activity) in the last 7 days using the 13-item Summary of Diabetes Self-care Behaviors Scale (range 0-91, higher = more frequent self-management behaviors).

    Time frame: One week (7 days), last week of the intervention

  3. Diabetes distress

    Diabetes distress measured using the Problem Areas in Diabetes scale; range 0-80; higher score = higher diabetes distress

    Time frame: Baseline and follow-up (immediately after the intervention)

  4. Self-management motivation

    Motivation and attitudes about behavioral diabetes self-management utilizing the 9-item Motivation and Attitudes Toward Changing Health measure (range: 9-45, higher scores = greater motivation/more positive attitude).

    Time frame: Baseline and follow-up (immediately after the intervention)

  5. Self-reported physical activity

    Self-reported moderate and vigorous physical activity using the International Physical Activity Questionnaire (scored as metabolic equivalent units per week)

    Time frame: Baseline and follow-up (immediately after the intervention)

  6. Objectively measured physical activity

    FitBit-sensed step count (weekly average)

    Time frame: 30 days (during the intervention period)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to the very small size of this study, data will not be shared, as there is risk of identifying participants.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 13 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Dec 2026 and completion Jul 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jul 15, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Dec 1, 2026was Jun 2026
CompletionEst.
Jan 1, 2027was Jul 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Dec 1, 2026
Nov 9, 2026
Study completion
Jul 30, 2026→Jan 1, 2027
Nov 9, 2026
Enrollment
40→45
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jun 30, 2026→Dec 1, 2026
    Study completion Jul 30, 2026→Jan 1, 2027
    Enrollment 40→45
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07065721
Collaborators
Scripps Health
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Oct 2, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Jessica L McCurley, PhD, MPH
Contact
jlmccurley@sdsu.edu
619-594-2132
Jessica L McCurley, PhD MPH
principal investigator · San Diego State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion